{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:57:11Z","timestamp":1791572231042,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["23212MFDS230"],"award-info":[{"award-number":["23212MFDS230"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00332632"],"award-info":[{"award-number":["RS-2024-00332632"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lanwpc.2024.101242","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:53:43Z","timestamp":1741607623000},"page":"101242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-8826","authenticated-orcid":false,"given":"Hwa Yeon","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-6123","authenticated-orcid":false,"given":"Jae Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lanwpc.2024.101242_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2213-8587(23)00086-4","article-title":"Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment","volume":"11","author":"Stefan","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101242_bib2","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/hep.26563","article-title":"Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study","volume":"58","author":"Stender","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101242_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101242_bib4","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101242_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lanwpc.2024.101242_bib6","article-title":"Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials","volume":"377","author":"He","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101242_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13098-022-00924-8","article-title":"Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"14","author":"Yu","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101242_bib8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/dom.15017","article-title":"Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility","volume":"25","author":"Nerild","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101242_bib9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101242_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101242_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101242_bib12","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s11695-019-03760-4","article-title":"Incidence and risk factors for cholelithiasis after bariatric surgery","volume":"29","author":"Guzm\u00e1n","year":"2019","journal-title":"Obes Surg"},{"issue":"9403","key":"10.1016\/j.lanwpc.2024.101242_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101242_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2016.03.005","article-title":"EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones","volume":"65","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.lanwpc.2024.101242_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/phar.2688","article-title":"Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: a nationwide cohort study","volume":"42","author":"Dong","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101242_bib16","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.2337\/dc22-1095","article-title":"Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. food and drug administration adverse event reporting system","volume":"46","author":"He","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lanwpc.2024.101242_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40264-024-01434-4","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of gallbladder and bile duct disease among patients with type 2 diabetes: a population-based cohort study","volume":"47","author":"Shapiro","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101242_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/aje\/kwp411","article-title":"Presence of gallstones or kidney stones and risk of type 2 diabetes","volume":"171","author":"Weikert","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101242_bib19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3346\/jkms.2008.23.4.644","article-title":"Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men","volume":"23","author":"Chang","year":"2008","journal-title":"J\u00a0Korean Med Sci"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101242_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12876-022-02149-5","article-title":"The association between hypertension and the risk of gallstone disease: a cross-sectional study","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.lanwpc.2024.101242_bib21","article-title":"Gallstones in patients with chronic liver diseases","volume":"2017","author":"Li","year":"2017","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.lanwpc.2024.101242_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cgh.2022.04.010","article-title":"The natural history of asymptomatic gallstones: a longitudinal study and prediction model","volume":"21","author":"Morris-Stiff","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.lanwpc.2024.101242_bib23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"issue":"5778","key":"10.1016\/j.lanwpc.2024.101242_bib24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1124234","article-title":"Metagenomic analysis of the human distal gut microbiome","volume":"312","author":"Gill","year":"2006","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.lanwpc.2024.101242_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dom.12748","article-title":"Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"1-3","key":"10.1016\/j.lanwpc.2024.101242_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","article-title":"Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects","volume":"179","author":"Keller","year":"2012","journal-title":"Regul Pept"},{"issue":"7","key":"10.1016\/j.lanwpc.2024.101242_bib27","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2018-01008","article-title":"New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs","volume":"104","author":"Gether","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lanwpc.2024.101242_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.gastro.2007.04.007","article-title":"Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis","volume":"133","author":"Marzioni","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.lanwpc.2024.101242_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.lanwpc.2024.101242_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","article-title":"Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and drug administration","volume":"182","author":"Woronow","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lanwpc.2024.101242_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524002360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524002360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:08:30Z","timestamp":1745003310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606524002360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"alternative-id":["S2666606524002360"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101242","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101242"}}